ClinicalTrials.gg
TerminatedNCT05374720CILTUBEUpdated Jun 12, 2026

Analysis of the Molecular Composition of Tubal Cilia in Patients With or Without Ectopic Pregnancy

An interventional study of salpingectomy and hysterectomy in Salpingectomy, Hysterectomy and Primary Ciliary Dyskinesia, sponsored by Centre Hospitalier Intercommunal Creteil. Terminated at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Centre Hospitalier Intercommunal Creteil · Not applicable, Interventional, and Other

Why this study was terminated
The inclusion objective was not achieved. Given the exploratory nature of the study, we have decided not to extend the study
Phase
Not applicable
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Primary Ciliary Dyskinesia associated with abnormalities of lateralization of organs (with existence of a situs inversus in 50% of cases) and secondary fertility disorders related in humans to abnormalities of mobility of sperm but very little data on the structure and function of tubal cilia in women

Read the detailed description

Primary Ciliary Dyskinesia (DCP) is a rare genetic disease (1 in 15,000 individuals at birth), which manifests itself in chronic respiratory infections (bronchopneumopathies and rhinosinusitis type) associated with abnormalities of lateralization of organs (with existence of a situs inversus in 50% of cases) and secondary fertility disorders related in humans to abnormalities of sperm mobility. However, there is very little data in the literature on the structure and function of tubal cilia in women with DCP.

Before considering a study of tubal cilia in patients with DCP, it seems necessary to specify in DCP patients or not DCP, the molecular and morphological composition of tubal cilia and to look for ciliary abnormalities in case of GEU

02

Conditions studied

  • Salpingectomy
  • Hysterectomy
  • Primary Ciliary Dyskinesia
  • Ectopic Pregnancy

Keywords

  • miscarriage
  • tubal cilia
03

In context

Ciliary Motility Disorders

79 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.

This study's enrollment of 61 is above the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.

Browse Ciliary Motility Disorders studies →

Lead sponsor

Centre Hospitalier Intercommunal Creteil is the lead sponsor of 131 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with scheduled salpingectomy (Ectopic pregnancy, hysterectomy for prolapsus, adenomyosis or myomectomy)
  • Major patients ( >18 years)

Exclusion criteria

Exclusion Criteria:

  • Patient not willing to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Salpingectomy for Extra-Uterine Pregnancy

    patients with salpingectomy for Ectopic Pregnancy

    Procedure: salpingectomy

  • Sham comparator
    hysterectomies

    patients with hysterectomy for prolapsus, adenomyosis or myomectomy

    Procedure: hysterectomy

Interventions

  • Proceduresalpingectomy

    Removal of one of the fallopian tubes.

  • Procedurehysterectomy

    remove the uterus, whole or only part. It may also involve the removal of the cervix, ovaries, fallopian tubes and other surrounding structures.

06

What researchers measure

Primary outcomes

  1. morphological of tubal cilia

    Molecular compositor of tubal ciliar by immunofluorescence study of 14 proteins in vivo and in vitro (tissue cells from patient fallopian tubes)

    Time frame: through study completion, an average of 6 week after surgery

  2. Molecular difference in tubal cilia between patients with or without GEU salpingectomy

    compares molecular compositor of tubal ciliar by immunofluorecence study of 14 proteins in vivo and in vitro between patients with or without GEU salpingectomy

    Time frame: through study completion, an average of 6 week after surgery

  3. molecular tubal cilia

    Ultrastructure morphology of tubal cell cilia by electron microscopy

    Time frame: through study completion, an average of 6 week after surgery

  4. functional composition of tubal cell by video microscopy

    amplitude of moment by video microscopy

    Time frame: through study completion, an average of 6 week after surgery

  5. functional composition of tubal cell by video microscopy

    frequency of moment by video microscopy

    Time frame: through study completion, an average of 6 week after surgery

07

Study locations

1 site
  • Centre Hospitalier Intercommunal Créteil
    Créteil, Val-deMarne 94000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Oct 2023, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
May 16, 2022
StartActual
Nov 30, 2022
Primary completionActual
Oct 9, 2023
CompletionActual
Oct 9, 2023
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05374720
Responsible party
Sponsor
First posted
May 16, 2022
Start date
Nov 30, 2022
Primary completion
Oct 9, 2023
Completion
Oct 9, 2023
Last update
Jun 12, 2026

Study contacts

Rana i MITRI-FRANGIEH
principal investigator · Centre Hospitalier Intercommunal Créteil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion